Bardin Hill Management Partners LP Decreases Position in Enhabit, Inc. (NYSE:EHAB)

Bardin Hill Management Partners LP decreased its stake in Enhabit, Inc. (NYSE:EHAB) by 88.6% in the second quarter, Holdings Channel.com reports. The firm owned 16,966 shares of the company’s stock after selling 131,432 shares during the period. Enhabit comprises about 0.1% of Bardin Hill Management Partners LP’s holdings, making the stock its 24th biggest position. Bardin Hill Management Partners LP’s holdings in Enhabit were worth $151,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. SummerHaven Investment Management LLC lifted its position in Enhabit by 2.8% in the second quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company’s stock worth $549,000 after buying an additional 1,660 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Enhabit by 7.2% in the 1st quarter. Oppenheimer & Co. Inc. now owns 26,224 shares of the company’s stock worth $306,000 after acquiring an additional 1,768 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Enhabit by 13.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the company’s stock valued at $166,000 after purchasing an additional 1,875 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Enhabit by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock worth $443,000 after purchasing an additional 2,078 shares during the period. Finally, Quarry LP raised its position in Enhabit by 242.2% in the 2nd quarter. Quarry LP now owns 3,703 shares of the company’s stock worth $33,000 after purchasing an additional 2,621 shares during the period.

Insiders Place Their Bets

In other news, Director Jeffrey Bolton purchased 5,000 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were acquired at an average cost of $8.01 per share, with a total value of $40,050.00. Following the completion of the acquisition, the director now owns 78,877 shares of the company’s stock, valued at $631,804.77. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.90% of the stock is currently owned by corporate insiders.

Enhabit Stock Performance

Shares of EHAB stock opened at $7.55 on Wednesday. The firm has a market cap of $378.43 million, a price-to-earnings ratio of -4.55 and a beta of 1.82. Enhabit, Inc. has a 52-week low of $7.12 and a 52-week high of $11.74. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.73. The company’s 50 day moving average is $8.56 and its 200 day moving average is $9.28.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The business had revenue of $260.60 million for the quarter, compared to the consensus estimate of $265.99 million. Enhabit had a positive return on equity of 1.61% and a negative net margin of 0.84%. During the same period last year, the business posted $0.04 EPS. On average, sell-side analysts anticipate that Enhabit, Inc. will post 0.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Bank of America cut their target price on Enhabit from $9.00 to $8.00 and set an “underperform” rating on the stock in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.35.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.